Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy
- 15 September 2016
- journal article
- review article
- Published by Springer Nature in Updates in Surgery
- Vol. 68 (3) , 235-239
Abstract
Borderline resectable pancreatic cancer is now recognized as a distinct clinical entity. In these cases, neoadjuvant treatment could maximize the potential for an R0 resection and avoid R1/R2 resections. In fact, by analyzing, the current literature is evident that approximately one-third of initially borderline resectable pancreatic tumors may undergo successful resection following neoadjuvant therapy. However, the enormous difficulties in achieving a consensus and the variability in therapeutic algorithms have delayed progress in establishing strong evidence-based practices for diagnosis and treatment. In addition, the absence of a unique definition of borderline resectable pancreatic cancer remains a great obstacle for planning a therapeutic strategy and surgical decision-making. If on the one hand, we can finally say that the presence of only few prospective trials generates no strong data to support a specific neoadjuvant therapy regimen in borderline resectable pancreatic cancer, on the other hand, there are many studies on patients with borderline resectable pancreatic cancer who receive neoadjuvant therapy that can enjoy an R0 resection with similar outcomes to up-front resectable disease.Keywords
This publication has 27 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?The Oncologist, 2012
- Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic CancerAnnals of Surgical Oncology, 2011
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of DiseaseJournal of the American College of Surgeons, 2008
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative TherapyAnnals of Surgical Oncology, 2006
- Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Postoperative Adjuvant Chemoradiation Improves SurvivalAnnals of Surgery, 1997
- Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 PatientsAnnals of Surgery, 1995